INDP

Company Overview — What Does Indaptus Therapeutics, Inc. Do?

Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as chronic hepatitis B virus and human immunodeficiency virus infection, which is in Phase 2 clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York. Indaptus Therapeutics, Inc. (INDP) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Jeffrey A. Meckler and employs approximately 6 people, headquartered in NEW YORK, New York. With a market capitalization of $4M, INDP is one of the notable companies in the Healthcare sector.

Indaptus Therapeutics, Inc. (INDP) Stock Rating — Avoid (April 2026)

As of April 2026, Indaptus Therapeutics, Inc. receives a Avoid rating with a composite score of 24.3/100 and 1 out of 5 stars from the Blank Capital Research quantitative model.INDP ranks #4,256 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Indaptus Therapeutics, Inc. ranks #769 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

INDP Stock Price and 52-Week Range

Indaptus Therapeutics, Inc. (INDP) currently trades at $2.02. The stock gained $0.17 (9.2%) in the most recent trading session. The 52-week high for INDP is $13.40, which means the stock is currently trading -84.9% from its annual peak. The 52-week low is $0.27, putting the stock 647.9% above its annual trough. Recent trading volume was 108K shares, suggesting relatively thin trading activity.

Is INDP Overvalued or Undervalued? — Valuation Analysis

Indaptus Therapeutics, Inc. (INDP) carries a value factor score of 12/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 0.78x, versus the sector average of 2.75x.

At current multiples, Indaptus Therapeutics, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Indaptus Therapeutics, Inc. Profitability — ROE, Margins, and Quality Score

Indaptus Therapeutics, Inc. (INDP) earns a quality factor score of 18/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -343.2%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -231.1% versus the sector average of -33.1%.

Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

INDP Debt, Balance Sheet, and Financial Health

Indaptus Therapeutics, Inc. has a debt-to-equity ratio of 49.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 2.88x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $6M.

INDP has a beta of 4.23, meaning it is more volatile than the broader market — a $10,000 investment in INDP would be expected to move 322.7% more than the S&P 500 on any given day. The stability factor score for Indaptus Therapeutics, Inc. is 7/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Indaptus Therapeutics, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Indaptus Therapeutics, Inc. reported revenue of $0 and earnings per share (EPS) of $-2.98. Net income for the quarter was $-16M. Operating income came in at $-15M.

In Q3 2025, Indaptus Therapeutics, Inc. reported revenue of $0 and earnings per share (EPS) of $-2.98. Net income for the quarter was $-3M. Operating income came in at $-3M.

In Q2 2025, Indaptus Therapeutics, Inc. reported revenue of $0 and earnings per share (EPS) of $-9.09. Net income for the quarter was $-5M. Operating income came in at $-4M.

In Q1 2025, Indaptus Therapeutics, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.32. Net income for the quarter was $-5M. Operating income came in at $-5M.

Over the past 8 quarters, Indaptus Therapeutics, Inc. has experienced revenue contraction from $0 to $0. Investors analyzing INDP stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

INDP Dividend Yield and Income Analysis

Indaptus Therapeutics, Inc. (INDP) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

INDP Momentum and Technical Analysis Profile

Indaptus Therapeutics, Inc. (INDP) has a momentum factor score of 46/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 24/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

INDP vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Indaptus Therapeutics, Inc. (INDP) ranks #769 out of 838 stocks based on the Blank Capital composite score. This places INDP in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing INDP against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full INDP vs S&P 500 (SPY) comparison to assess how Indaptus Therapeutics, Inc. stacks up against the broader market across all factor dimensions.

INDP Next Earnings Date

No upcoming earnings date has been announced for Indaptus Therapeutics, Inc. (INDP) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy INDP? — Investment Thesis Summary

The quantitative profile for Indaptus Therapeutics, Inc. suggests caution. The quality score of 18/100 flags below-average profitability. The value score of 12/100 indicates premium valuation. High volatility (stability score 7/100) increases portfolio risk.

In summary, Indaptus Therapeutics, Inc. (INDP) earns a Avoid rating with a composite score of 24.3/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on INDP stock.

Related Resources for INDP Investors

Explore more research and tools: INDP vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare INDP head-to-head with peers: INDP vs AZN, INDP vs SLGL, INDP vs VMD.